Atara Biotherapeutics (ATRA) PT Lowered to $20 at Stifel on Negative tab-cel Feedback from FDA, but Overall Data Seen as Supportive of Approval
Go back to Atara Biotherapeutics (ATRA) PT Lowered to $20 at Stifel on Negative tab-cel Feedback from FDA, but Overall Data Seen as Supportive of Approval| (NASDAQ: ATRA) | Delayed: 9.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.60 | 52 Week High | $40.80 | |||
| Open | $9.60 | 52 Week Low | $12.45 | |||
| Day High | $9.60 | P/E | N/A | |||
| Day Low | $9.60 | EPS | $0.00 | |||
| Volume | 1 | |||||
